ICBP90: A New Protein Linked to Cancer
Author Information
Author(s): Mousli M, Hopfner R, Abbady A-Q, Monté D, Jeanblanc M, Oudet P, Louis B, Bronner C
Primary Institution: Inserm U392, Faculté de Pharmacie, France
Hypothesis
ICBP90 may be an intermediary actor in the E2F-induced TopoIIα expression, and that its expression may be deregulated in cancer cells vs noncancer cells.
Conclusion
ICBP90 is overexpressed in cancer cells and may play a role in regulating TopoIIα expression.
Supporting Evidence
- ICBP90 expression is higher in cancer cell lines compared to noncancer cell lines.
- Overexpression of E2F-1 increases ICBP90 and TopoIIα expression.
- ICBP90 levels peak during specific phases of the cell cycle in normal cells.
Takeaway
Scientists found a new protein called ICBP90 that is more active in cancer cells than in normal cells, which might help explain why some cancer treatments work better than others.
Methodology
The study involved identifying ICBP90's role in regulating TopoIIα expression through various cell lines and experiments including E2F-1 overexpression.
Limitations
The study does not fully elucidate the mechanisms by which ICBP90 regulates TopoIIα expression in cancer cells.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website